Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results
Objective. Systemic lupus erythematosus (SLE) is an autoimmune systemic disease and its pathogenesis has not yet been completely clarified. Patients with SLE show a deranged lipid metabolism, which can contribute to the immunopathogenesis of the disease and to the accelerated atherosclerosis. Resolv...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/5264195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566713100533760 |
|---|---|
| author | Luca Navarini Tiziana Bisogno Domenico Paolo Emanuele Margiotta Alessandra Piccoli Silvia Angeletti Alice Laudisio Massimo Ciccozzi Antonella Afeltra Mauro Maccarrone |
| author_facet | Luca Navarini Tiziana Bisogno Domenico Paolo Emanuele Margiotta Alessandra Piccoli Silvia Angeletti Alice Laudisio Massimo Ciccozzi Antonella Afeltra Mauro Maccarrone |
| author_sort | Luca Navarini |
| collection | DOAJ |
| description | Objective. Systemic lupus erythematosus (SLE) is an autoimmune systemic disease and its pathogenesis has not yet been completely clarified. Patients with SLE show a deranged lipid metabolism, which can contribute to the immunopathogenesis of the disease and to the accelerated atherosclerosis. Resolvin D1 (RvD1), a product of the metabolism of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA), acts as a specialized proresolving mediator which can contribute in restoring the homeostasis in inflamed tissues. The aim of the present pilot study is to evaluate plasma levels of RvD1 in patients with SLE and healthy subjects, investigating its potential role as a biomarker of SLE and assessing its relationship with disease activity and laboratory parameters. Methods. Thirty patients with SLE and thirty age- and sex-matched healthy subjects (HSs) have been consecutively recruited at Campus Bio-Medico University Hospital. RvD1 plasma levels were measured by ELISA according to the manufacturer’s protocol (Cayman Chemical Co.). RvD1 levels were compared using Mann–Whitney test. Discriminatory ability for SLE has been evaluated by the area under the ROC curve. Results. Lower levels of RvD1, 45.6 (35.5–57.4) pg/ml, in patients with SLE have been found compared to HSs, 65.1 (39.43–87.95) pg/ml (p=0.0043). The area under the ROC curve (AUC) for RvD1 was 0.71 (95% CI: 0.578–0.82) and the threshold value of RvD1 for the classification of SLE was <58.4 pg/ml, sensitivity 80% (95% CI: 61.4–92.3), and specificity 63.3% (95% CI: 43.9–80.1), likelihood ratio 2.2 (95% CI: 1.3–3.6). Conclusions. The present preliminary study allows hypothesizing a dysregulation of RvD1 in patients with SLE, confirming the emerging role of bioactive lipids in this disease. |
| format | Article |
| id | doaj-art-d6f2a36b36c94ee1a3a1cd3cc1f9ec52 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-d6f2a36b36c94ee1a3a1cd3cc1f9ec522025-02-03T01:03:29ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/52641955264195Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary ResultsLuca Navarini0Tiziana Bisogno1Domenico Paolo Emanuele Margiotta2Alessandra Piccoli3Silvia Angeletti4Alice Laudisio5Massimo Ciccozzi6Antonella Afeltra7Mauro Maccarrone8Unit of Allergology, Immunology and Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli, ItalyUnit of Allergology, Immunology and Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Biochemistry and Molecular Biology, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Clinical Laboratory Science, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Geriatrics, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Clinical Laboratory Science, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Allergology, Immunology and Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyUnit of Biochemistry and Molecular Biology, Department of Medicine, Università Campus Bio-Medico di Roma, Via Álvaro del Portillo 21, 00128 Rome, ItalyObjective. Systemic lupus erythematosus (SLE) is an autoimmune systemic disease and its pathogenesis has not yet been completely clarified. Patients with SLE show a deranged lipid metabolism, which can contribute to the immunopathogenesis of the disease and to the accelerated atherosclerosis. Resolvin D1 (RvD1), a product of the metabolism of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA), acts as a specialized proresolving mediator which can contribute in restoring the homeostasis in inflamed tissues. The aim of the present pilot study is to evaluate plasma levels of RvD1 in patients with SLE and healthy subjects, investigating its potential role as a biomarker of SLE and assessing its relationship with disease activity and laboratory parameters. Methods. Thirty patients with SLE and thirty age- and sex-matched healthy subjects (HSs) have been consecutively recruited at Campus Bio-Medico University Hospital. RvD1 plasma levels were measured by ELISA according to the manufacturer’s protocol (Cayman Chemical Co.). RvD1 levels were compared using Mann–Whitney test. Discriminatory ability for SLE has been evaluated by the area under the ROC curve. Results. Lower levels of RvD1, 45.6 (35.5–57.4) pg/ml, in patients with SLE have been found compared to HSs, 65.1 (39.43–87.95) pg/ml (p=0.0043). The area under the ROC curve (AUC) for RvD1 was 0.71 (95% CI: 0.578–0.82) and the threshold value of RvD1 for the classification of SLE was <58.4 pg/ml, sensitivity 80% (95% CI: 61.4–92.3), and specificity 63.3% (95% CI: 43.9–80.1), likelihood ratio 2.2 (95% CI: 1.3–3.6). Conclusions. The present preliminary study allows hypothesizing a dysregulation of RvD1 in patients with SLE, confirming the emerging role of bioactive lipids in this disease.http://dx.doi.org/10.1155/2018/5264195 |
| spellingShingle | Luca Navarini Tiziana Bisogno Domenico Paolo Emanuele Margiotta Alessandra Piccoli Silvia Angeletti Alice Laudisio Massimo Ciccozzi Antonella Afeltra Mauro Maccarrone Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results Journal of Immunology Research |
| title | Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results |
| title_full | Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results |
| title_fullStr | Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results |
| title_full_unstemmed | Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results |
| title_short | Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results |
| title_sort | role of the specialized proresolving mediator resolvin d1 in systemic lupus erythematosus preliminary results |
| url | http://dx.doi.org/10.1155/2018/5264195 |
| work_keys_str_mv | AT lucanavarini roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT tizianabisogno roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT domenicopaoloemanuelemargiotta roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT alessandrapiccoli roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT silviaangeletti roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT alicelaudisio roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT massimociccozzi roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT antonellaafeltra roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults AT mauromaccarrone roleofthespecializedproresolvingmediatorresolvind1insystemiclupuserythematosuspreliminaryresults |